Atypical Antipsychotics: Efficacy Across Bipolar Disorder Subpopulations
J Clin Psychiatry 2005;66(suppl 3):20-27
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Atypical antipsychotic medications, used as monotherapy or as adjunctive therapy with mood stabilizers,
have shown efficacy and tolerability for 4 subpopulations of patients with bipolar disorder:
patients with mixed mania, patients with psychotic episodes, children and adolescents, and the elderly.
Patients experiencing mixed mania generally respond poorly to lithium therapy and are more
difficult to treat than patients with pure mania. Atypical antipsychotics are increasingly being considered
for this bipolar subpopulation because of their efficacy as antimanic agents, and because they are
less likely to cause as many or as severe adverse events as conventional antipsychotics. Atypical antipsychotics
have also demonstrated beneficial effects as monotherapy and adjunctive therapy for bipolar
I disorder patients experiencing psychotic states. In addition, they have shown effectiveness and
tolerability in small-scale and open-label trials and case studies with pediatric and geriatric bipolar